Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, ab3dd1)
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mitoxantrone hydrochloride liposome (PLM60) is a liposomal formulation of the synthetic anthracenedione antineoplastic agent mitoxantrone. Developed by CSPC Pharmaceutical Group, it is designed to improve the pharmacokinetic profile of conventional mitoxantrone by increasing circulation time and enhancing accumulation in tumor tissues while reducing systemic toxicities, particularly cardiotoxicity. Mitoxantrone acts as a DNA intercalator and a topoisomerase II inhibitor, leading to DNA strand breaks and inhibition of DNA synthesis. In the context of the First Affiliated Hospital Xi'an Jiaotong University, it is being evaluated as a component of a modified BEAM (or BEAC) conditioning regimen (including carmustine, etoposide, and cytarabine) for patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation (ASCT). The liposomal formulation was approved by China's NMPA in 2022 for the treatment of relapsed or refractory peripheral T-cell lymphoma.
- Brand names
- Duoenda
- Other names
- mitoxantrone liposomemitoxantrone hydrochloride liposomal injection
02
Targets
DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, ab3dd1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, ab3dd1).